Docs-2feffects+of+homeopathy+in+weight+loss.ppt 4r6b24

Effects of homeopathy in reducing weight, body fat mass and percent body fat. A randomized, doubleLinda Kimcontrolled clinical trial blind,Dr. placebo Dr. Pam Swan Dr. Robert Waters Michael Smith Jennifer Orlowski

What is homeopathy?  Like

Cures Like  Law of Minimums  Stimulate body’s own healing process  Ie.

Ipecac

Effectiveness of Homeopathy  A meta-analysis

of placebo controlled clinical trials demonstrated that homeopathic effects are not due to placebo alone, there was a 2.45 times greater effect than placebo  Meta-analysis of 107 controlled trials showed 76% of those studies were effective

Obesity in Adults  Estimated

97 million adults in US are overweight or obese  Overweight defined as BMI of 25 to 29.9 kg/m² and obesity is a BMI of greater than or equal to 30 kg/m²

Risk of Obesity Hypertension  Dyslipidemia  Type 2 Diabetes  Coronary heart disease  Stroke  Gallbladder disease  Osteoarthritis  Sleep apnea  Respiratory problems  Endometrial, breast, prostate, or colon cancer 

What were the questions we asked?  Does

homeopathy promote more weight loss than placebo?  What is the short term efficacy of a homeopathic weight loss product?

What did the treatment address?  Reducing

food cravings  Respond to normal satiety  Improving metabolism  Controlling hypoglycemia  Mental/emotional issues  exercise

The product we used in the study  Weight

Control ™ manufactured by Dolisos America Inc.

Homeopathics Included  Anacardium

orientale  Antimonium crudum  Calcarea carbonica  Graphites  Iodium  Nuv Vomica

Remedies and their roles in weight loss 

Sx

Anacar dium

Antimoni um

Calcera

Graphite s

Iodium

Nux vomica

Curbing Hunger

X

X

X

X

X

X

X

X

X

Improving metabolis m Hypo glycemia

X

Over eating mood

X X

X

X

X

Craving sugar

X

Craving Fat

X

X

Methods  Recruited

people from Phoenix metropolitan area  Initial screening was done by phone using inclusion/exclusion criteria  Qualified 35 patient, 30 completed

Methods  Inclusion:  Male/female

21-45 y.o  BMI 30-39 kg/m²  Confirmed menstrual period prior to enrollment  Able to comply with study requirements: informed consent, 2 office visits, follow up monitoring, avoid other diet programs and perform exercise program

Methods  Exclusion:  Pregnant,

lactating, or wanting to become

pregnant  Obesity of endocrine origin  History of bulimia or anorexia  History of alcohol or drug addiction

Methods 4 week trial  Take 1 tablet 4 times per day sublingual  Exercise 4 times per week  Wear pedometer daily  Fill out daily questioners  Weekly phone monitoring  Office visit 2 times 

Methods: Office visit  Physical  BP,

exam:

pulse, respiration rate, temperature  Weight, height, body measurements hip and waist  Metabolic testing with a Bod Pod {ADD HERE}

Outcome Parameters  

 

Body weight changes  BMI, lean body mass, fat mass, percent body fat Body change measurements  Circumference of waist and hip  Hip/waist ratio Metabolic testing  Respiratory exchange rate Questionaires  VAS of hunger, satiety, thirst, mood [daily]  Pedometer log  Quality of Life Index SF-36, defecation pattern, satisfaction w/ intervention, compliance [2 times]  Hamilton Depression scale [2 times]

Results  Of

the 35 people enrolled 30 completed the study, giving a 14% drop out rate  Screened 126 patients with 230 inquires

Body Measurement changes  These

were not significant between the active group and the placebo group.  There weight decreases and body measurement changes in active group from baseline to end of treatment  This suggest a pattern of weight reduction, but not a conclusive difference

Exercise Compliance  There

was a significant change (p < . 05) noted with exercise compliance between active and placebo  Patients in active group recorded more exercise on average than placebo

Questionaires These were significant (P < .05) The daily questionaire asking about hunger, satiety, thirst, mood and defecation should overall improvement in active group as compared to placebo  Results from SF –36 confirmed results  Improvements may have been attributed to increase incidence of exercise in active group 

Depressive Scale  No

conclusive change in scale and patient compliance between placebo and active group

Adverse Effects  None

were reported  The only complaint reported by some patient was amount of time required to dissolve pill

Conclusion It was not conclusively shown that this product promoted weight loss, however the time interval may have been to short to draw a significant conclusion  It was conclusively shown that the active group did notice changes in quality of life issues, suggesting that the product may be effective at a longer interval 

Future Studies  We

should do a 3 month study to determine if weight loss would be significant at a longer time interval.

Statistical Analysis  Each

body measurements were analyzed using a mean, standard deviation, t test and Wilcoxon’s signed rank test. Confidence intervals of 95% were utilized to detect statistical significance